• Investing
  • Stock
Round Table Thoughts
  • Economy
  • Editor’s Pick
Home Economy New report highlights ‘booming’ transgender surgery industry that is raking in billions: ‘Damage being done’
Economy

New report highlights ‘booming’ transgender surgery industry that is raking in billions: ‘Damage being done’

by July 2, 2024
by July 2, 2024 0 comment
Share
0
FacebookTwitterPinterestWhatsapp

A new report from a conservative think tank is shedding light on the size of the ‘booming’ transgender surgery industry today that has swelled into the billions of dollars and continues to grow and raises a variety of concerns. 

The new report American Principles Project (APP) shows that the transgender ‘medicine’ industry has exploded into a massive system where total revenues for transgender drugs and surgeries in 2023 were estimated to surpass $4.4 billion. That number, according to the study, could exceed $7.8 billion by 2030.

My organization, American Principles Project, has been concerned about the entire transgender agenda as it pertains to children for quite some time now,’APP President Terry Schilling told Fox News Digital. 

‘We know that there are obvious physical and psychological consequences to it, but we wanted to figure out why the industry was growing so much, why such a small population was getting so much attention and media, you know, favorable attention in our cultural arena, and we figured out very quickly that there’s a lot of money here.’

The report outlines how lifelong use of cross-sex hormones could cost up to $300,000 with surgical transitions costing $150,000. Additionally, the potentially damaging side effects from transition surgery like cancer, nerve damage, chronic pain, sexual dysfunction and mental health issues lead to more medical expenses.

The report explains that transgender surgery providers, including Cedars Sinai, the Regents of the University of Michigan, the Mount Sinai Health System and several others, are believed to have brought in over $100 million in revenue in 2022 from transgender surgeries, and pharmaceutical companies like Pfizer and AbbVie brought in $74 million and $51 million, respectively.

‘There’s so many physical bad things that happen to you and side effects that we’ve known about for a few years, but it didn’t really explain why people were still pushing them towards this,’ Schilling told Fox News Digital. 

‘I like to think that most human beings are normally good, and they don’t want to cause harm to people. So what would push people into these procedures and what would push people into encouraging other people to go through these painful procedures that cause so much dysfunction and harm to them? And it makes a lot more sense when you realize that there are billions and billions of dollars at stake.’

The report states that 1.6 million Americans now identify as transgender, including 300,000 individuals between 13 and 17 years old. 

‘Given the lucrative nature of this industry, it seems likely medical practitioners will continue to recommend and administer these drugs and procedures for as long as they feel safe from liability,’ APP said in a press release. 

‘However, many detransitioners are beginning to emerge, facing regret as well as significant health issues resulting from their transition. Their public stories—as well as potential lawsuits— may eventually lead to a reckoning for the industry, resulting in transgender medicine going the way of the lobotomy.’

Schilling told Fox News Digital that the estimates in the report are likely to be conservative and that pro-gender transition activists have boasted that the industry could surpass $200 billion per year, larger than the film industry. 

‘We wanted America and the world really to know, just how much, money was being put into this industry,’ Schilling told Fox News Digital.

‘It is vitally important that the American people see the reality of what is happening: the damage being done by these practices as well as the financial incentives which keep the industry going despite the consequences,’ Schilling said in a press release.

‘And policymakers must recognize that we cannot afford to stand idle while the victims of this industry pile up. Although it is possible that growing liability will one day put an end to this malpractice, we should not wait for that to happen. Government action is necessary, and it cannot come a moment too soon.’ 

Fox News reached out to Pfizer, Abbvie, Cedars Sinai, the Regents of the University of Michigan and the Mount Sinai Health System for comment.

This post appeared first on FOX NEWS
You Might Also Like
  • Supreme Court to hear arguments in Trump presidential immunity case on April 25
  • New York lawmakers pass third budget extension as stalemate continues
  • Supreme Court prepares for new term by looking back, with likely impact on 2024 elections
  • Biden appears to mix up Ukraine and Gaza in meeting with Italian prime minister
Share
0
FacebookTwitterPinterestWhatsapp

previous post
White House to take questions on camera for 1st time since debate
next post
Biden’s ex-press secretary Jen Psaki to sit down with House GOP panel probing chaotic Afghanistan withdrawal

You may also like

Trump says NY Judge Merchan ‘thinks he is above the...

April 25, 2024

Israel prepares for Iran attack amid warnings that regime is...

August 4, 2024

‘Everyone’s mad’: Fight to avoid government shutdown shatters House GOP...

July 25, 2024

Indiana Republicans propose partisan school board races

February 9, 2023

Dems who accused Trump of trying to jail opponents voice...

April 1, 2023

Biden called out for ‘factual error’ in ‘Bidenomics’ tweet, after...

July 17, 2023

Trump leading Biden ahead of CNN Presidential Debate, support from...

June 27, 2024

Nvidia Stock Slumps as Dow Futures Edge Lower

November 26, 2024

Deadly explosion in Tel Aviv leaves one dead, more wounded

July 19, 2024

Bernie Sanders urges people to focus on policy, not age...

July 7, 2024

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • US Strikes Iran: What Comes Next For Stocks?

      June 22, 2025
    • The NASDAQ 100, On The Brink Of A Breakout, Needs Help From This Group

      June 21, 2025
    • Tesla agrees to first deal to build China’s largest grid-scale battery power plant

      June 21, 2025
    • Oil prices rise more than 1% as Israel vows to intensify attacks on Iran

      June 20, 2025
    • RRG Alert Tech Vaults to ‘Leading’—Is XLK Signaling a New Rally?

      June 20, 2025

    Popular Posts

    • 1

      Biden appointee played key role in recruiting Chinese...

      June 25, 2024 3,602 views
    • 2

      Trump-era China sanctions ended by Biden may be...

      June 27, 2024 2,881 views
    • 3

      Walz’s honeymoon with China gets fresh scrutiny as...

      August 9, 2024 2,582 views
    • 4

      Shein’s global ambitions leaves some cybersecurity experts fearful...

      July 10, 2024 2,543 views
    • 5

      Harris VP pick spent years promoting research facility...

      August 29, 2024 2,421 views

    Categories

    • Economy (7,009)
    • Editor's Pick (2,143)
    • Investing (538)
    • Stock (2,623)

    Popular Posts

    • 1

      Biden appointee played key role in recruiting Chinese businesses to Delaware: ‘Longtime friends’

      June 25, 2024
    • 2

      Trump-era China sanctions ended by Biden may be revived under new House GOP bill

      June 27, 2024
    • 3

      Walz’s honeymoon with China gets fresh scrutiny as Harris camp blasts ‘lying’ critics

      August 9, 2024
    • 4

      Shein’s global ambitions leaves some cybersecurity experts fearful of Chinese spy threats

      July 10, 2024
    • 5

      Harris VP pick spent years promoting research facility that collaborated with ‘Chinese military company’

      August 29, 2024

    Latest News

    • US Strikes Iran: What Comes Next For Stocks?

      June 22, 2025
    • The NASDAQ 100, On The Brink Of A Breakout, Needs...

      June 21, 2025
    • Tesla agrees to first deal to build China’s largest grid-scale...

      June 21, 2025

    Categories

    • Economy (7,009)
    • Editor's Pick (2,143)
    • Investing (538)
    • Stock (2,623)

    Disclaimer: RoundTableThoughts.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 RoundTableThoughts.com. All Rights Reserved.

    Round Table Thoughts
    • Investing
    • Stock
    Round Table Thoughts
    • Economy
    • Editor’s Pick

    Read alsox

    New Jersey Democrat organization that Sen...

    November 17, 2023

    A look at Donald Trump’s arraignment...

    April 2, 2023

    Congress Can Restore the Integrity of...

    December 7, 2022
    Sign In

    Keep me signed in until I sign out

    Forgot your password?

    Password Recovery

    A new password will be emailed to you.

    Have received a new password? Login here